Which drug better protects GCA Patients' hearts? large study investigates
NCT ID NCT07459335
First seen Mar 12, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This study looked at over 1,600 people with giant cell arteritis (GCA), a condition causing blood vessel inflammation. Researchers compared two drugs, tocilizumab and methotrexate, to see which better prevents major heart problems like heart attack, stroke, or death. Using French health records, the study aimed to find the safer, more effective option for managing heart risks in GCA.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHP_ Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
APHP_ Hôpital Saint-Antoine
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.